Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to considerJavier Rodríguez‐Carrio, Marjan A. Versnel|RMD Open|2023Cited by 38
Amlexanox inhibits production of type I interferon and suppresses B cell differentiation <i>in vitro</i>: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseasesAlbin Björk, Marjan A. Versnel|RMD Open|2025Cited by 2